The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease?
Abstract
The cardiovascular system is regulated by hemodynamic and neurohumoral mechanisms. These regulatory systems play a key role in modulating cardiac function, vascular tone, and structure. Although neurohumoral systems are essential in vascular homeostasis, they become maladaptive in disease states such as hypertension, coronary disease, and heart failure. The clinical success of ACE inhibitors has led to efforts to block other humoral systems. Neutral endopeptidase (NEP) is an endothelial cell surface zinc metallopeptidase with similar structure and catalytic site. NEP is the major enzymatic pathway for degradation of natriuretic peptides, a secondary enzymatic pathway for degradation of kinins, and adrenomedullin. The natriuretic peptides can be viewed as endogenous inhibitors of the renin angiotensin system. Inhibition of NEP increases levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) of myocardial cell origin, and C-type natriuretic peptide (CNP) of endothelial cell origin as well as bradykinin and adrenomedullin. By simultaneously inhibiting the renin-angiotensin-aldosterone system and potentiating the natriuretic peptide and kinin systems, vasopeptidase inhibitors reduce vasoconstriction, enhance vasodilation, improve sodium/water balance, and, in turn, decrease peripheral vascular resistance and blood pressure and improve local blood flow. Within the blood vessel wall, this leads to a reduction of vasoconstrictor and proliferative mediators such as angiotensin II and increased local levels of bradykinin (and, in turn, nitric oxide) and natriuretic peptides. Preliminary clinical experiences with vasopeptidase inhibitors are encouraging. Thus, the combined inhibition of ACE and neutral endopeptidase is a new and promising approach to treat patients with hypertension, atherosclerosis, or heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
Palmer, R. M. J., Ferrige, A. G., & Moncada, S. (1987) · Nature · doi:10.1038/327524a0 · Cited by 10,704
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Mancini, G. B. J., Henry, G. C., Macaya, C., O'Neill, B. J., Pucillo, A. L., Carere, R. G., Wargovich, T. J., Mudra, H., Lu¨scher, T. F., Klibaner, M. I., et al. (1996) · Circulation · doi:10.1161/01.cir.94.3.258 · Cited by 1,057
Self-citationColucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L. E., Givertz, M. M., Liang, C.-S., Neibaur, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430403 · Cited by 911
Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the Human
Burnett, J. C., Kao, P. C., Hu, D. C., Heser, D. W., Heublein, D., Granger, J. P., Opgenorth, T. J., & Reeder, G. S. (1986) · Science · doi:10.1126/science.2935937 · Cited by 891
Plasma bradykinin in angio-oedema
Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09137-x · Cited by 706
Effects of synthetic atrial natriuretic factor on renal function and renin release
Burnett, J. C. J., Granger, J. P., & Opgenorth, T. J. (1984) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1984.247.5.f863 · Cited by 659
(2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432019 · Cited by 526
Rouleau, J. L., Pfeffer, M. A., Stewart, D. J., Isaac, D., Sestier, F., Kerut, E. K., Porter, C. B., Proulx, G., Qian, C., & Block, A. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02602-7 · Cited by 396
Self-citationWiemer, G., Schölkens, B. A., Becker, R. H., & Busse, R. (1991) · Hypertension · doi:10.1161/01.hyp.18.4.558 · Cited by 349
Vasopeptidase inhibition and angio-oedema
Messerli, F. H., & Nussberger, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02596-4 · Cited by 223
Schiffrin, E. L., & Deng, L.-Y. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.699 · Cited by 192
Effect of captopril and enalapril on endothelial function in hypertensive patients.
Creager, M. A., & Roddy, M. A. (1994) · Hypertension · doi:10.1161/01.hyp.24.4.499 · Cited by 183
ACE Inhibitors Promote Nitric Oxide Accumulation to Modulate Myocardial Oxygen Consumption
Zhang, X., Xie, Y.-W., Nasjletti, A., Xu, X., Wolin, M. S., & Hintze, T. H. (1997) · Circulation · doi:10.1161/01.cir.95.1.176 · Cited by 181
Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo
Ferro, C. J., Spratt, J. C., Haynes, W. G., & Webb, D. J. (1998) · Circulation · doi:10.1161/01.cir.97.23.2323 · Cited by 175
Effects of Omapatrilat in Low, Normal, and High Renin Experimental Hypertension
Trippodo, N. C. (1998) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00404-4 · Cited by 156
Angioedema due to angiotensin-converting enzyme inhibitors
Agostoni, A., Cicardi, M., Cugno, M., Zingale, L. C., Gioffré, D., & Nussberger, J. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00107-1 · Cited by 147
Angioedema due to ACE inhibitors: increased risk in patients of African origin
Gibbs, Lip, & Beevers (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00093.x · Cited by 147
Richards, M., Wittert, G., Crozier, I., Espiner, E. A., Yandle, T. G., Ikram, H., & Frampton, C. M. (1993) · Journal of Hypertension · doi:10.1097/00004872-199304000-00011 · Cited by 145
The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins
Blais, C., Marceau, F., Rouleau, J.-L., & Adam, A. (2000) · Peptides · doi:10.1016/s0196-9781(00)00348-x · Cited by 135
Self-citationAngiotensin II Receptor Blockers in Patients with ACE Inhibitor–Induced Angioedema
Warner, K. K., Visconti, J. A., & Tschampel, M. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19294 · Cited by 130
McClean, D. R., Ikram, H., Garlick, A. H., Richards, M., Nicholls, M. G., & Crozier, I. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00741-5 · Cited by 110
Taddei, S., Virdis, A., Ghiadoni, L., Mattei, P., & Salvetti, A. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816040-00006 · Cited by 107
Trippodo, N. C., Fox, M., Monticello, T. M., Panchal, B. C., & Asaad, M. M. (1999) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199912000-00003 · Cited by 100
Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin
Lisý, O., Jougasaki, M., Schirger, J. A., Chen, H. H., Barclay, P. T., & Burnett, J. C. J. (1998) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1998.275.3.f410 · Cited by 89
Trippodo, N. C., Robl, J. A., Asaad, M. M., et al. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12124-1 · Cited by 86
Effects of Cilazapril on Vascular Structure and Function in Essential Hypertension
Kiowski, W., Linder, L., Nüesch, R., & Martina, B. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.371 · Cited by 81
Blais, C., Rouleau, J.-L., Brown, N. J., Lepage, Y., Spence, D., Munoz, C., Friborg, J., Geadah, D., Gervais, N., & Adam, A. (1999) · Immunopharmacology · doi:10.1016/s0162-3109(99)00133-2 · Cited by 78
Self-citationTikkanen, T., Tikkanen, I. T., Rockell, M. D., Allen, T. J., Johnston, C. I., Cooper, M. E., & Burrell, L. M. (1998) · Hypertension · doi:10.1161/01.hyp.32.4.778 · Cited by 77
Intengan, H. D., & Schiffrin, E. L. (2000) · Hypertension · doi:10.1161/01.hyp.35.6.1221 · Cited by 66
Chen, H. H., Lainchbury, J. G., Matsuda, Y., Harty, G. J., & Burnett, J. C. J. (2001) · Hypertension · doi:10.1161/01.hyp.38.2.187 · Cited by 56
Renal response to candoxatrilat in patients with heart failure
Good, J. M., Peters, A. M., Wilkins, M. R., Jackson, N. C., Oakley, C. M., & Cleland, J. G. F. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00561-4 · Cited by 44
Blais, C., Fortin, D., Rouleau, J. L., Molinaro, G., & Adam, A. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38947-5 · Cited by 41
Self-citationd’Uscio, L. V., Quaschning, T., Burnett, J. C. J., & Lüscher, T. F. (2001) · Hypertension · doi:10.1161/01.hyp.37.1.28 · Cited by 41
Patel, S., Steeds, R. P., Channer, K. S., & Samani, N. J. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00176-4 · Cited by 39
Zhang, X., Nasjletti, A., Xu, X., & Hintze, T. H. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199804000-00023 · Cited by 25
Asmar, R. G. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)00618-x · Cited by 22
Sympathetic Responses to Atrial Natriuretic Peptide in Patients with Congestive Heart Failure
Azevedo, E. R., Newton, G. E., Parker, A. B., Floras, J. S., & Parker, J. D. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200001000-00017 · Cited by 22
Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors
Yusuf, S., Lonn, E., Bosch, J., & Gerstein, H. C. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909061013 · Cited by 20
Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin
Lisý, O., Jougaski, M., Schirger, J., Chen, H., Barclay, P. T., & Burnett, J. (1998) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(98)90067-7 · Cited by 20
Jv, M., Illiano, S., & Pm, V. (1992) · PubMed · Cited by 7
Cited by
B-type natriuretic peptide in cardiovascular disease
de Lemos, J. A., McGuire, D. K., & Drazner, M. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13976-1 · Cited by 1,067
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease
Remuzzi, G., Perico, N., Macia, M., & Ruggenenti, P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09911.x · Cited by 505
Drugs targeting the renin–angiotensin–aldosterone system
Zaman, M. A., Oparil, S., & Calhoun, D. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd873 · Cited by 439
Sarzani, R., Salvi, F., Dessì-Fulgheri, P., & Rappelli, A. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f624a0 · Cited by 284
Natriuretic peptides in cardiovascular diseases: current use and perspectives
Volpe, M., Rubattu, S., & Burnett, J. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht466 · Cited by 277
Metadata
- Authors
- Corti, R., Burnett Jr, J. C., Rouleau, J. L., Ruschitzka, F., & Lüscher, T. F.
- Venue
- Circulation
- Published
- 2001-10-09
- Volume
- 104
- Issue
- 15
- Pages
- 1856-1862
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2129272798
- Cited by
- 300
- References
- 41
- FWCI
- 18.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.